Astrazeneca Leading In Covid-19 Vaccine Race, Moderna Not Far Behind: WHO
AstraZeneca's experimental Covid-19 vaccine is probably the world's leading candidate and most advanced in terms of development, the World Health Organization's (WHO) chief scientist said on Friday.
The British drugmaker has already begun large-scale, mid-stage human trials of the vaccine, which was developed by researchers at University of Oxford.
This week, AstraZeneca signed its tenth supply-and-manufacturing deal.
"Certainly in terms of how advanced they are, the stage at which they are, they are I think probably the leading candidate," WHO chief scientist Soumya Swaminathan told a news conference.
"So it's possible they will have results quite early."
Swaminathan said Moderna's Covid-19 vaccine candidate was "not far behind" AstraZeneca's, among more than 200 candidates, 15 of which have entered clinical trials.
ALSO READ: Coronavirus LIVE: Vaccine tests need over $30 bn in 12 months, says WHO
"We do know that Moderna's vaccine is also going to go into phase three clinical trials, probably from the middle of July, and so that vaccine candidate is not far behind," she said.
"But I think AstraZeneca certainly has a more global scope at the moment in terms of where they are doing and planning their vaccine trials."
The WHO is in talks with multiple Chinese manufacturers, including Sinovac, on potential vaccines, as well as with Indian researchers, Swaminathan said.
She called for drugmakers to consider collaborating on Covid-19 vaccine trials, similar to the WHO's ongoing Solidarity trial for drugs. A WHO-led coalition fighting the pandemic on Friday asked government and private sector donors to help raise $31.3 billion in the next 12 months to develop and deliver tests, treatments and vaccines for the disease. The initiative is called the ACT-Accelerator.
Andrew Witty, Special Envoy for the ACT-Accelerator, said it was important to consider a "portfolio of research efforts" for vaccines.
"It's still very early days in this journey, we may be super lucky - which would be terrific - and have an early win," Witty said. "Even if it takes 12 to 18 months that would be without precedent, the world's fast development of vaccine."
JPMorgan Deploys AI Chatbot To Revolutionize Research And Productivity
JPMorgan has deployed an AI-based research analyst chatbot to enhance productivity among its workforce, with approximate... Read more
Private Equity And Banks: The Complex Web Of Leverage
Private equity has emerged as a significant force in the global financial landscape, driving substantial growth and inve... Read more
Financial Watchdog Highlights Unresolved Vulnerabilities In Shadow Banking Sector
The world’s leading financial stability watchdog has issued a warning about the unresolved vulnerabilities within the ... Read more
JPMorgan And Small Caps Lead Market Rally: A Sign Of Economic Optimism
In a week marked by strong financial performance, JPMorgan Chase & Co. reported a 25% rise in profits, and US small-... Read more
Big Banks Vs. Regional Banks: The Battle For Market Share
The financial industry is a competitive landscape where big banks and regional banks vie for market share. Each type of ... Read more
The Evolution Of Philanthropic Advisory Services In Private Banks
The landscape of philanthropic advisory services provided by private banks has undergone a significant transformation. T... Read more